Skip to Content

Isatuximab in combination with RVd improves MRD negativity

At this year’s ASH annual meeting, latest results from the phase III GMMG-HD7 trial will be presented. The trial indicates that addition of isatuximab to standard of care in patients with newly-diagnosed multiple myeloma significantly decreases detection of myeloma cells.

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top